| |
 |
 |
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system. |
| Company Name |
Title of Study |
Update Date |
| Merck, Ltd. |
A prospective, multicentre, observational study on the predictive factors of ovarian response in ovulation induction (OI) with intrauterine insemination (IUI) of a Gonal-f NGP low-dose step-up regimen |
2010-01-26 |
| Novartis (Taiwan) Co., Ltd. |
Observational study of imatinib and blood level in CML patients after administration of imatinib mesylate |
2010-01-25 |
| Novartis (Taiwan) Co., Ltd. |
An Observational Study of Imatinib Dose Escalation in GIST Patients with Progressive Disease |
2010-01-25 |
| Janssen-Cilag Taiwan |
TEAMS: Topiramate in the treatment of Epilepsy: 1st Add-on vs. Mono-therapy study in neuro-Surgical patients. |
2010-01-11 |
| AstraZeneca Taiwan |
Real life Effectiveness of Symbicort® Maintenance and Reliever Therapy® (SMART) in Asthma Patients across Asia: SMARTASIA |
2009-10-26 |
| Pfizer Ltd. Taiwan |
A multinational, multicentre, Randomized, double-blind study to assess the efficacy and safety of oral Sildenafil 20mg TID or Placebo when added to Bosentan in the treatment of subjects, aged 18 years AND ABOVE, with pulmonary arterial hypertension (PAH) |
2009-10-06 |
| Pfizer Ltd. Taiwan |
PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF-SELECTED (FLEXIBLE) QUIT DATE |
2009-09-23 |
| Bayer Taiwan Co., Ltd. |
Community-Acquired RTI Pathogen Surveillance (CARTIPS) in Asia: Analysis of Antimicrobial Resistance Patterns |
2009-08-27 |
| Bayer Taiwan Co., Ltd. |
MiCo - Mirena or conventional medical treatment for menorrhagia |
2009-08-25 |
| Bayer Taiwan Co., Ltd. |
IoproMide (UltrAvist®) – to Gain further information on tolerability and safety in X-ray Examination |
2009-08-25 |
| Sanofi-aventis Taiwan Co., Ltd. |
Usage and Satisfaction of Lantus SoloSTAR® among Diabetic |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Registry on Cardiac rhythm disorders: an international, observational, prospective survey assessing the control of Atrial Fibrillation in Asia Pacific. |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Persistence on Glimepiride-Metformin(Amaryl M®) fixed combination in everyday praCtice in Asian Type 2 diabetES patients |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Observational Registry in Full Spectrum of Acute Coronary Syndromes |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Asia Pacific Breast Initiatives – II
|
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Adjuvant Colon Cancer with ELOXatin® / 5FU based regimen: ACCElox
|
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
Active implementation of Quality of Life (QOL) assessment in clinical practice for patients with advanced NSCLC and comparison of QOL and response endpoints |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
A registry to assess the strategies used to achieve blood pressure target in Taiwanese uncontrolled hypertensive patients |
2009-08-19 |
| Sanofi-aventis Taiwan Co., Ltd. |
A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension
A Controlled, Randomised, Open-label, Multicentre, Phase IIIb/IV study. |
2009-08-19 |
| Bayer Taiwan Co. Ltd. |
International, multi-center post authorization surveillance study on the use of Nebido(r) to assess tolerability and treatment outcomes in daily clinical practice (IPASS Nebido(r)) |
2009-06-30 |
|
|
|
|
